Compare Nutanix Inc (NTNX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Natera Inc. Common Stock — how do they compare? Nutanix Inc trades at $69.82 (market cap $19.72B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.9× Nutanix Inc's market cap, and Nutanix Inc is more actively traded (2,236,075 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Natera Inc. Common Stock for 0 Days on average.
| NTNX | NTRA | |
|---|---|---|
Market Cap | $19.72B | $57.03B |
Volume | 2,236,075 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $74.63 | $425.64 |
52-Week Low | $34.41 | $179.42 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $18.88B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $72.88, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and positive analyst sentiment. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive 86.8% gross margins. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms.
Outlook remains positive with 62.5% analyst buy ratings and $76.11 consensus price target, though elevated P/E of 14.1 and negative ROE of -395.76% warrant caution. Key risks include supply chain pressures and competitive IT services market, while AI growth initiatives and external storage expansion present upside potential.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
